| Literature DB >> 17560108 |
Neil Moss1, Steffen Breitfelder, Raj Betageri, Pier F Cirillo, Tazmeen Fadra, Eugene R Hickey, Thomas Kirrane, Rachel R Kroe, Jeffrey Madwed, Richard M Nelson, Christopher A Pargellis, Kevin C Qian, John Regan, Alan Swinamer, Carol Torcellini.
Abstract
Discovery of the pyrazole-naphthyl urea class of p38 MAP kinase inhibitors typified by the clinical candidate BIRB 796 has encouraged further exploration of this particular scaffold. Modification to the part of the inhibitor that occupies the adenine/ATP binding site has resulted in a new way to obtain potent inhibitors that possess favorable in vitro and in vivo properties.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17560108 DOI： 10.1016/j.bmcl.2007.05.042
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823